骨髓纤维化临床试验中的贫血相关响应终点:当前趋势和需要重新达成共识
Barbara J Klencke1, Rafe Donahue1, Boris Gorsh2
1Sierra Oncology, a GSK company, San Mateo, CA 94404, USA.
Future oncology (London, England)
|February 6, 2024
概括
目前用于骨髓纤维化治疗的药物,如JAK抑制剂,往往会使贫血状况恶化. 这项研究强调了对贫血反应的不一致报告,并主张建立一个新的共识小组,以标准化定义,以便更好地评估治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 骨髓纤维化治疗,主要是JAK抑制剂,是标准的护理,但经常加剧贫血.
- 在骨髓纤维化临床试验中,贫血反应一直是报告不足的疗效终点,导致数据不一致.
- 莫梅洛替尼 (Momelotinib) 是第一个FDA为患有贫血的骨髓纤维化病患者表示的治疗方法.
研究的目的:
- 分析不同标准如何影响骨髓纤维化治疗报告的贫血相关益处.
- 倡导在骨髓纤维化临床试验中对贫血反应的标准化定义.
主要方法:
- 对JAK1/JAK2/ACVR1抑制剂mamelotinib的第三期临床试验数据的审查.
- 基于不同评估标准的贫血相关终点的分析.
- 专家经验应用程序,以突出报告不一致性.
主要成果:
- 评估贫血反应的不同标准为骨髓纤维化治疗带来了各种各样的报告益处.
- 目前的报告缺乏一致性和分析细节,阻碍了准确的疗效评估.
- 莫梅洛替尼的适用性突显出需要对贫血反应进行有针对性的评估.
结论:
- 标准化贫血反应的定义对于评估髓纤维化疗法至关重要.
- 建议建立一个专家共识小组,以建立一致和透明的报告标准.
- 改善贫血反应评估将提高对髓纤维化治疗疗效的理解.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Factors Affecting Erythropoiesis
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...


